Before coming to AscentGene, Dr. Ge was the senior vice president and chief scientific officer of ProteinOne Inc., a biotechnology company in Bethesda, MD. Through ProteinOne, he won 1.4 million dollars of government funding for ProteinOne’s R&D and helped the company to become a world-leading protein company.
Dr. Ge received his Ph.D. in molecular biology and biochemistry from Columbia University in New York, where he identified and cloned the first alternative splicing factor ASF from human cells. He then obtained his postdoctoral training in Dr. Robert Roeder’s laboratory at Rockefeller University, where he identified and cloned the first general transcriptional coactivator and established an in vitro transcription system reconstituted with highly purified transcription factors. Dr. Ge was the Head of Unit on Transcriptional Mechanisms at NIH before starting ProteinOne.
Over the past 25 years, Dr. Ge has been invited to be a manuscript reviewer for a number of scientific journals, a grant reviewer for the NIH study section and the England Wellcome Foundation, and a member of the scientific advisory committees for many international conferences. Dr. Ge has published 34 research articles in top journals including Cell, Science, Molecular Cell, PNAS, EMBO J., and J. Biol. Chem. He has also invented three patented technologies.

Dr. He has had extensive education and experience in the biomedical and financial fields. He obtained his M.D. from Peking Union Medical College, his Ph.D. in biochemistry from the University of Rochester, and his MBA from Johns Hopkins University. Dr. He was a senior scientist at the National Institutes of Health and has published more than 30 research papers in peer-reviewed journals. Dr. He was a first vice president of wealth management at the Smith Barney/Citigroup before joining AGI.

Dr. Zhang has extensive experience in small molecule and biological drug discovery in both academic and industrial settings. She obtained her M.D. from Capital Medical University and Ph.D. in Cellular & Molecular Biology from Chiba University, Japan, as well as completing her Postdoctoral Studies(JSPS Fellowship) there. Then, she joined the Division of Endocrinology and Metabolism in the Department of Internal Medicine at Washington University School of Medicine as a Research Associate and studied the role of pancreatic transcription factors in diabetes. When she worked as a Postdoctoral Research Associate at Texas A&M University Health Science Center, she used mouse models to study prostate tumor development. She was Research Consultant in the Otsuka Maryland Medicinal Laboratories (OMML), assisting in the discovery of anti-thrombotic small molecules, in vitro (cell based assays) and in vivo (xenograft models) evaluation of immunotoxins. Before she joined AscentGene, Inc, Dr, Zhang was an Academic Scientist in the Center for Biomolecular Therapeutics (CBT) at the Department of Biochemistry and Molecular Biology (University of Maryland School of Medicine), where she focused on the discovering lead S100A1 inhibitors for Alzheimer’s disease and S100B inhibitors for melanoma therapies. Dr. Zhang has published more than 10 research paper in peer-reviewed journals.